<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00278954</url>
  </required_header>
  <id_info>
    <org_study_id>GMX01</org_study_id>
    <nct_id>NCT00278954</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.</brief_title>
  <official_title>A Phase III, Multicenter, Open-Label Study To Evaluate The Efficacy, Safety, and Pharmacokinetics of GammaplexÂ® in Primary Immunodeficiency Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bio Products Laboratory</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bio Products Laboratory</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to see if GAMMAPLEX is efficacious with respect to Food
      and Drug Administration (FDA) minimal requirements (no more than 1 serious, acute, bacterial
      infection per subject per year) in subjects with Primary Immunodeficiency Diseases (PID). The
      secondary objectives are to assess the safety and tolerability of GAMMAPLEX and to determine
      if GAMMAPLEX has a pharmacokinetic (PK) profile comparable with that of intact Immunoglobulin
      G (IgG) in subjects with PID.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Efficacy Variable The primary variable is the number of serious, acute, bacterial
      infections/subject/year, and it will be based on the total of all of the following events as
      defined by the FDA: bacterial Pneumonia, bacteremia/sepsis, osteomyelitis/septic arthritis,
      visceral abscess, and bacterial meningitis.

      Secondary Efficacy Variables Secondary efficacy will be determined by using the following
      variables: number of days of work/school missed because of infection per subject year; number
      and days of hospitalizations because of infection per subject year; number of visits to
      physicians for acute problems and/or number of visits to hospital emergency rooms per subject
      year; other infections documented by fever or a positive result on a radiograph and/or
      culture; number of infectious episodes per subject per year; number of days on therapeutic
      antibiotics.These data will be entered into the subject diary, confirmed by the physician,
      and entered on the electronic-CRF (e-CRF).

      Safety Variables. The variables used to assess safety will be the following: adverse events
      (AEs); vital signs; clinical laboratory tests and Direct Coombs' Test; transmission of
      viruses; physical examination.

      Test product, dose/mode of administration, batch number(s): The GAMMAPLEX dose is 300-800
      mg/kg/infusion (milligram per killgram per infusion) every 21 or 28 days, intravenously. At
      least 2 batches will be used in this study and no more than 1 batch in any given infusion.

      Duration of treatment:

      The total duration of treatment is 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Serious, Acute, Bacterial Infections (SABIs) Per Subject Per Year in Subjects With Primary Immunodeficiency Disease.</measure>
    <time_frame>12 months</time_frame>
    <description>By assessing the number of serious, acute, bacterial infections per subject per year in subjects with Primary Immunodeficiency disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Pharmacokinetic (PK) Half-Life of Immunoglobulin G (IgG)</measure>
    <time_frame>-5, 0, 60 minutes (min), 24, 48 hours (hrs), 4, 7, 14, 21 and 28 days</time_frame>
    <description>Blood samples for PK analysis were obtained and analysed at 10 different time points, i.e. -5, 0, 60 minutes (min), 24, 48 hours (hrs), 4, 7, 14, 21 and 28 days, at an infusion visit following 6 months of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Pharmacokinetic (PK) Clearance of Immunoglobulin G (IgG)</measure>
    <time_frame>-5, 0, 60 min, 24, 48 hrs, 4, 7, 14, 21 and 28 days</time_frame>
    <description>Blood samples for PK analysis were obtained and analysed at 10 different time points, i.e. -5, 0, 60 minutes (min), 24, 48 hours (hrs), 4, 7, 14, 21 and 28 days, at an infusion visit following 6 months of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Pharmacokinetic (PK) Volume of Distribution (Vz)of Immunoglobulin G (IgG)</measure>
    <time_frame>-5, 0, 60 min, 24, 48 hrs, 4, 7, 14, 21 and 28 days</time_frame>
    <description>Blood samples for PK analysis were obtained and analysed at 10 different time points, i.e. -5, 0, 60 minutes (min), 24, 48 hours (hrs), 4, 7, 14, 21 and 28 days, at an infusion visit following 6 months of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Pharmacokinetic (PK) Mean Residence Time (MRT) for Inmuunoglobulin G (IgG)</measure>
    <time_frame>-5, 0, 60 min, 24, 48 hrs, 4, 7, 14, 21 and 28 days</time_frame>
    <description>Blood samples for PK analysis were obtained and analysed at 10 different time points, i.e. -5, 0, 60 minutes (min), 24, 48 hours (hrs), 4, 7, 14, 21 and 28 days, at an infusion visit following 6 months of treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Primary Immunodeficiency</condition>
  <condition>Common Variable Hypogammaglobulinemia</condition>
  <condition>X-linked Hypogammaglobulinemia</condition>
  <condition>Hypogammaglobulinemia</condition>
  <condition>Immunodeficiency With Hyper-IgM</condition>
  <condition>Wiskott-Aldrich Syndrome</condition>
  <arm_group>
    <arm_group_label>Gammaplex</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Gammaplex</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gammaplex (Intravenous immunoglobulin)</intervention_name>
    <description>GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously for 12 months.</description>
    <arm_group_label>Gammaplex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. The subject is 3 years of age or older, of either sex, belonging to any ethnic
             group, and above a minimum weight of 27.5 kg. This weight is based on the amount of
             blood required for testing. If subject is participating in the PK segment, the minimum
             weight required is 37 kg.

             2. The subject has a primary immunodeficiency disease, which has as a significant
             component of hypogammaglobulinemia and/or antibody deficiency (e.g. (exempli gratia /
             for example), common variable immunodeficiency, X-linked and autosomal forms of
             agammaglobulinemia, hyper-immunoglobulin M (hyper-IgM) syndrome, Wiskott-Aldrich
             Syndrome). Isolated deficiency of a single IgG subclass, or of specific antibodies
             without hypogammaglobulinemia per se, does not qualify for inclusion.

             3. The subject has been receiving licensed or investigational (Phase III or IIIb)
             immunoglobulin intravenous (IGIV) replacement therapy at a dose that has not changed
             by + 50% of the mean dose for at least 3 months before study entry and is between 300
             and 800 mg/kg/infusion. The infusion interval must be between 21 and 28 days
             inclusive. The subject must have maintained a trough level at least 300 mg/dL
             (milligram per decilitre) above baseline serum IgG levels (defined as before
             initiation of any gamma globulin treatment for that subject). The trough level must be
             600 mg/dL.

             4. Trough levels of IgG and dose of IGIV, treatment intervals, and the trade name of
             the IGIV treatments used for the last 2 consecutive routine (licensed or
             investigational product) must be documented for each subject before the first infusion
             in this study can be administered.

             5. If a subject is a female of child-bearing potential, she must have a negative
             result on an Human Chorionic Gonadotrophin (HCG)-based pregnancy test.

             6. If a subject is a female who is or becomes sexually active, she must practice
             contraception by using a method of proven reliability for the duration of the study.

             7. The subject is willing to comply with all aspects of the protocol, including blood
             sampling, for the duration of the study.

             8. The subject has signed an informed consent form (if at least 18 years old) or the
             subject's parent or legal guardian has signed the informed consent form. If
             appropriate, the subject has signed a child assent form (See Section 12.3).

        Exclusion Criteria:

          -  Subjects will be excluded if any of the following exclusion criteria are met:

               1. The subject has a history of any severe anaphylactic reaction to blood or any
                  blood-derived product.

               2. The subject is known to be intolerant to any component of GAMMAPLEX, such as
                  sorbitol (i.e.(id est / that is) , intolerance to fructose).

               3. The subject has selective immunoglobulin A (IgA) deficiency, history of reaction
                  to products containing IgA, or has a history of antibodies to IgA.

               4. Subjects who have completed the study and subjects who have withdrawn cannot
                  participate in the study for a second time.

               5. The subject is currently receiving, or has received, any investigational agent,
                  other than an immune serum globulin (ISG) preparation that is being evaluated in
                  a Phase III or IIIb study, within the prior 3 months.

               6. The subject has been exposed to blood or any blood product or derivative within
                  the last 6 months, other than a commercially available IGIV or other forms of
                  commercially available and licensed ISG or an ISG product that is in Phase III or
                  IIIb studies.

               7. The subject is pregnant or is nursing.

               8. The subject is positive for any of the following at screening:

                    -  Serological test for Human immunodeficiency virus (HIV) 1&amp;2, Hepatitis C
                       virus (HCV), or Hepatitis B surface antigen (HBsAg)

                    -  Nucleic Acid test (NAT) for HCV

                    -  NAT for HIV

               9. The subject, at screening, has levels greater than 2.5 times the upper limit of
                  normal as defined at the central laboratory of any of the following:

                    -  Alanine transaminase (ALT)

                    -  Aspartate transaminase (AST)

              10. The subject has a severe renal impairment (defined as serum creatinine greater
                  than 2 times the upper limit of normal or Blood urea nitrogen (BUN) greater than
                  2.5 times the upper limit of normal for the range of the laboratory doing the
                  analysis); the subject is on dialysis; the subject has a history of acute renal
                  failure.

              11. The subject is known to abuse alcohol, opiates, psychotropic agents, or other
                  chemicals or drugs, or has done so within the past 12 months.

              12. The subject has a history of deep vein thrombosis (DVT), or thrombotic
                  complications of IGIV therapy.

              13. The subject suffers from any acute or chronic medical condition (e.g., renal
                  disease or predisposing conditions for renal disease, coronary artery disease, or
                  protein losing state) that, in the opinion of the investigator, may interfere
                  with the conduct of the study.

              14. The subject has an acquired medical condition, such as chronic lymphocytic
                  leukemia, lymphoma, multiple myeloma, chronic or recurrent neutropenia (Absolute
                  neutrophil count (ANC) &lt; 1000 x 109/L).

              15. The subject is receiving the following medication:

                    -  Immunosuppressive drugs

                    -  The subject is receiving the following medication: Steroids (long-term
                       daily, &gt;0.15 mg /kg/day of prednisone or prednisolone of equivalent dose of
                       other corticosteroids) The requirement for burst or intermittent courses
                       would not exclude the subject.

                    -  Immunomodulatory drugs

              16. The subject has non-controlled arterial hypertension (systolic blood pressure &gt;
                  160 mmHg (millimeters of mercury) and/or diastolic blood pressure &gt; 100 mmHg).

              17. The subject has anemia (hemoglobin &lt; 10 g/dL) at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melvin Berger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rainbow Babies &amp; Children's Hospital, Cleveland, Ohio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergy Associates of the Palm Beaches</name>
      <address>
        <city>North Palm Beach</city>
        <state>Florida</state>
        <zip>33408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Allergy and Asthma Center PC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Centre, University Consultants in Allergy &amp; Immunology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital at Buffalo, Allergy Division</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy, Asthma &amp; Immunology Clinic, P.A.</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Centre</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington School of Medicine, Dept. of Pediatrics</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>989109-5235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bpl.co.uk</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2006</study_first_submitted>
  <study_first_submitted_qc>January 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2006</study_first_posted>
  <results_first_submitted>May 29, 2009</results_first_submitted>
  <results_first_submitted_qc>January 4, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 28, 2010</results_first_posted>
  <disposition_first_submitted>May 5, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>January 4, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 28, 2010</disposition_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Antibody Deficiency</keyword>
  <keyword>Common variable hypogammaglobulinemia</keyword>
  <keyword>X-linked hypogammaglobulinemia</keyword>
  <keyword>Hypogammaglobulinemia</keyword>
  <keyword>Immunodeficiency with hyper-IgM</keyword>
  <keyword>Wiskott-Aldrich Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Wiskott-Aldrich Syndrome</mesh_term>
    <mesh_term>Agammaglobulinemia</mesh_term>
    <mesh_term>Hyper-IgM Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Genetic Diseases, X-Linked</mesh_term>
    <mesh_term>Common Variable Immunodeficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First enrollment: 06 February 2006 Last subject completed: 06 November 2007 Seven investigative sites, all hospital clinics</recruitment_details>
      <pre_assignment_details>This was an open study. All enrolled subjects received study medication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Gammaplex</title>
          <description>All subjects received between 300 to 800 mg/kg/infusion of Gammaplex intravenously, every 21 day or 28 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gammaplex</title>
          <description>All subjects received between 300 to 800 mg/kg/infusion of Gammaplex intravenously, every 21 day or 28 days.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.0" spread="19.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Serious, Acute, Bacterial Infections (SABIs) Per Subject Per Year in Subjects With Primary Immunodeficiency Disease.</title>
        <description>By assessing the number of serious, acute, bacterial infections per subject per year in subjects with Primary Immunodeficiency disease.</description>
        <time_frame>12 months</time_frame>
        <population>Intent to Treat (ITT).</population>
        <group_list>
          <group group_id="O1">
            <title>Gammaplex</title>
            <description>All subjects received between 300 to 800 mg/kg/infusion of Gammaplex intravenously, every 21 day or 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Serious, Acute, Bacterial Infections (SABIs) Per Subject Per Year in Subjects With Primary Immunodeficiency Disease.</title>
          <description>By assessing the number of serious, acute, bacterial infections per subject per year in subjects with Primary Immunodeficiency disease.</description>
          <population>Intent to Treat (ITT).</population>
          <units>SABIs/subject/year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The estimated serious acute bacterial infection (SABI) rate was calculated by dividing no. of infections by no.of subject years. The exponential of the upper limit of the 98% 2-sided Confidence Interval (CI) gave the upper, 1-sided, 99% confidence bound, estimated using Poisson regression. The equivalent upper bound per subject year was obtained by dividing this figure by total subject years.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Poisson regression with log link</method>
            <param_type>SABI per subject per year</param_type>
            <param_value>0</param_value>
            <ci_percent>99</ci_percent>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>0.101</ci_upper_limit>
            <estimate_desc>Mean SABI rate = 0 per subject per year. 1-sided 99% upper confidence bound could not be calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Pharmacokinetic (PK) Half-Life of Immunoglobulin G (IgG)</title>
        <description>Blood samples for PK analysis were obtained and analysed at 10 different time points, i.e. -5, 0, 60 minutes (min), 24, 48 hours (hrs), 4, 7, 14, 21 and 28 days, at an infusion visit following 6 months of treatment.</description>
        <time_frame>-5, 0, 60 minutes (min), 24, 48 hours (hrs), 4, 7, 14, 21 and 28 days</time_frame>
        <population>Only 24 of the 45 evaluable subjects participated in the Pharmacokinetic part of the protocol. No data imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Gammaplex</title>
            <description>All subjects received between 300 to 800 mg/kg/infusion of Gammaplex intravenously, every 21 day or 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>The Pharmacokinetic (PK) Half-Life of Immunoglobulin G (IgG)</title>
          <description>Blood samples for PK analysis were obtained and analysed at 10 different time points, i.e. -5, 0, 60 minutes (min), 24, 48 hours (hrs), 4, 7, 14, 21 and 28 days, at an infusion visit following 6 months of treatment.</description>
          <population>Only 24 of the 45 evaluable subjects participated in the Pharmacokinetic part of the protocol. No data imputation.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.19" spread="19.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Pharmacokinetic (PK) Clearance of Immunoglobulin G (IgG)</title>
        <description>Blood samples for PK analysis were obtained and analysed at 10 different time points, i.e. -5, 0, 60 minutes (min), 24, 48 hours (hrs), 4, 7, 14, 21 and 28 days, at an infusion visit following 6 months of treatment.</description>
        <time_frame>-5, 0, 60 min, 24, 48 hrs, 4, 7, 14, 21 and 28 days</time_frame>
        <population>Only 24 of the 45 evaluable subjects participated in the Pharmacokinetic part of the protocol. No data imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Gammaplex</title>
            <description>All subjects received between 300 to 800 mg/kg/infusion of Gammaplex intravenously, every 21 day or 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>The Pharmacokinetic (PK) Clearance of Immunoglobulin G (IgG)</title>
          <description>Blood samples for PK analysis were obtained and analysed at 10 different time points, i.e. -5, 0, 60 minutes (min), 24, 48 hours (hrs), 4, 7, 14, 21 and 28 days, at an infusion visit following 6 months of treatment.</description>
          <population>Only 24 of the 45 evaluable subjects participated in the Pharmacokinetic part of the protocol. No data imputation.</population>
          <units>mL/day/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.585" spread="0.2508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Pharmacokinetic (PK) Volume of Distribution (Vz)of Immunoglobulin G (IgG)</title>
        <description>Blood samples for PK analysis were obtained and analysed at 10 different time points, i.e. -5, 0, 60 minutes (min), 24, 48 hours (hrs), 4, 7, 14, 21 and 28 days, at an infusion visit following 6 months of treatment.</description>
        <time_frame>-5, 0, 60 min, 24, 48 hrs, 4, 7, 14, 21 and 28 days</time_frame>
        <population>Only 24 of the 45 evaluable subjects participated in the Pharmacokinetic part of the protocol. No data imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Gammaplex</title>
            <description>All subjects received between 300 to 800 mg/kg/infusion of Gammaplex intravenously, every 21 day or 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>The Pharmacokinetic (PK) Volume of Distribution (Vz)of Immunoglobulin G (IgG)</title>
          <description>Blood samples for PK analysis were obtained and analysed at 10 different time points, i.e. -5, 0, 60 minutes (min), 24, 48 hours (hrs), 4, 7, 14, 21 and 28 days, at an infusion visit following 6 months of treatment.</description>
          <population>Only 24 of the 45 evaluable subjects participated in the Pharmacokinetic part of the protocol. No data imputation.</population>
          <units>dL/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.297" spread="0.0539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Pharmacokinetic (PK) Mean Residence Time (MRT) for Inmuunoglobulin G (IgG)</title>
        <description>Blood samples for PK analysis were obtained and analysed at 10 different time points, i.e. -5, 0, 60 minutes (min), 24, 48 hours (hrs), 4, 7, 14, 21 and 28 days, at an infusion visit following 6 months of treatment.</description>
        <time_frame>-5, 0, 60 min, 24, 48 hrs, 4, 7, 14, 21 and 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gammaplex</title>
            <description>All subjects received between 300 to 800 mg/kg/infusion of Gammaplex intravenously, every 21 day or 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>The Pharmacokinetic (PK) Mean Residence Time (MRT) for Inmuunoglobulin G (IgG)</title>
          <description>Blood samples for PK analysis were obtained and analysed at 10 different time points, i.e. -5, 0, 60 minutes (min), 24, 48 hours (hrs), 4, 7, 14, 21 and 28 days, at an infusion visit following 6 months of treatment.</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1" spread="23.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>An event was only included in the analysis of Adverse Events (AEs) if it had an onset date between the first Gammaplex infusion and 30 days after the last Gammaplex infusion, inclusive.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gammaplex</title>
          <description>All subjects received between 300 to 800 mg/kg/infusion of Gammaplex intravenously, every 21 day or 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (8.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <description>Chest pain, Possibly related - Resolved. This SAE occurred in the same subject who experienced Thrombosis and Syncope vasovagal.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <description>Viral gastroenteritis, Not related - Resolved</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <description>Bacterial pneumonia, Not related - Resolved Diagnosed prior to first Gammaplex infusion. Treatment for bacterial pneumonia began 4 days before the subject's first infusion in the study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <description>Basal cell carcinoma, 7 millimeter(mm) lesion on left side of nose, Not related - Resolved</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 8.1">Squamous cell carcinoma</sub_title>
                <description>Moderately differentiated squamous cell carcinoma, Not related - Resolved</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <description>Syncopal epsisode, vasovagal in etiology, Not related - Resolved. This Serious Adverse Event (SAE) occurred in the same subject who experienced Thrombosis and Chest pain.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <description>Pregnancy, Not related - Resolved</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <description>Blood clot to left arm, Possibly related - Resolved This SAE occurred in the same subject who also experienced Chest Pain and Syncope vasovagal.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (8.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Upper abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="22" subjects_affected="7" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="15" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Bronchitis acute</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="7" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="26" subjects_affected="17" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Athralgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="97" subjects_affected="18" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="19" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="10" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication of the Study results will be allowed only with prior written approval from Sponsor, said consent not to be unreasonably withheld. At the request of Sponsor, the Institution and/or Investigator shall delete any Confidential Information pertaining to Sponsor's Inventions from any proposed publications prior to submitting or presenting the materials. Any and all publications will give appropriate recognition of any support received from Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Margaret Stratford Bobbitt</name_or_title>
      <organization>Bio Products Laboratory</organization>
      <phone>+44 20 8258 2288</phone>
      <email>Margaret.Stratford-Bobbitt@bpl.co.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

